ACTRIMS Forum 2026 survey February 3, 2026 Recommend to a Colleague print Help make the NeuroSens coverage of the ACTRIMS Forum 2026 relevant to you. Complete the survey below to tell us what topics are of greatest interest to you. Question 1: Which of the following new topics is most interesting/relevant to you? (Pick one) Effect of cannabis on MS symptoms Effect of vitamin B6 on sphingosine-1-phosphate (S1P) Impact of GLP-1 agonists on MS Use of artificial intelligence in MS management Question 2: About which of the following topics would you like more information? (Pick one) Diagnostic guidelines for monitoring cognitive impairment Consensus on use of sNfL for guiding MS management Incidence/prevalence of NMOSD in Canada CAR-T therapy in MS Question 3: Which of the following is of greatest interest to you as a biomarker? (Pick one) sNfL GFAP Cervical spinal cord area Microglial density on TSPO-PET Paramagnetic rim lesions Question 4: About which oral disease-modifying therapy would you like more information? (Pick one) Teriflunomide Dimethyl fumarate Fingolimod Siponimod Ozanimod Cladribine Question 5: About which monoclonal antibody disease-modifying therapy would you like more information? (Pick one) Natalizumab Ocrelizumab Ofatumumab Rituximab Alemtuzumab Question 6: About which Bruton’s tyrosine kinase (BTK) inhibitor would you like more information? (Pick one) Tolebrutinib Fenebrutinib Remibrutinib Orelabrutinib Question 7: Which of the following trial results are most interesting/relevant to you? (Pick one) Effect of ocrelizumab on PIRA Ofatumumab in early RMS patients with minimal disability ORATORIO-HAND study of ocrelizumab in older PPMS patients PRIM study of pregnancy outcomes with ofatumumab Cladribine as an exit strategy for treatment discontinuation Question 8: Which of the following trials on novel therapies interests you the most? (Pick one) PERSEUS trial of tolebrutinib in PPMS FENtrepid trial of fenebrutinib vs. ocrelizumab in PPMS MOONSTONE trial of obexelimab in RMS Frexalimab phase II extension DAWN study of daratumumab in NMOSD Question 9: Which clinical question has the greatest relevance to you? (Pick one) Does cannabis adversely affect the gut microbiome? Are anti-CD20 agents effective as first-line therapy? Can MS precede EBV infection? Does gut barrier permeability contribute to immune dysregulation in MS? Is step count correlated with sNfL levels in PMS?
